Partnering is an integral part of our strategy at Vernalis. We actively in-license and out-license programmes as well as enter into research and development collaborations.  We seek to in-license late-stage, low risk assets that will complement our cough cold commercial strategy in the US, illustrated by our acquisition of the US rights to Moxatag®.

 

  • In-licensing opportunities sought to complement our US commercial strategy
  • Promising candidates ready for out-licensing now
  • Research partnerships

 

Established track-record with a number of large pharmaceutical companies

Partners include Genentech, Lundbeck, Novartis, Servier, Tris and others

Why partner with Vernalis?

We have a number of promising partnership opportunities

Sharing the risks and rewards of late stage development with suitably qualified partners

Out-licensing opportunities

Vernalis actively seeks late-stage, low risk assets

Suitable assets would complement our cough cold strategy in the US

In-licensing opportunities

Luminespib (AUY922) is an Hsp90 inhibitor that has been studied in a large number of phase I/II data and is indicated for the treatment of a broad range of cancers.

Read more about Luminespib (AUY922)

A selective FAAH (fatty acid amide hydrolase) inhibitor

V158866 is our lead molecule with potential application in pain and neurology indications.  This programme is currently on hold.

Read more about V158866

A selective Chk1 (checkpoint 1) inhibitor

V158411, is the lead molecule potentially indicated for treatment of a broad range of cancers 

Read more about V158411

Latest News

AGM Statement

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch